Company Profile · Healthcare

InMode Ltd

INMD · US
Country
USA
IPO date
Aug 8, 2019
Employees
660
Buffett Score
73/100
Strong
Market cap$810.8M
Revenue (TTM)$374.62M
EBITDA$71.15M
Profit margin20.69%
ROE12.33%
P/E (TTM)11.64
Forward P/E9.99
PEG2.9
EPS$1.21
52-week range$12.72 – $16.74
Analyst target$16.17
Analyst rating3.0 / 5

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

No reports on this stock in your language yet.